Sugi Predict

Sugi Predict / Compounds / SCHEMBL4592942

SCHEMBL4592942

SCHEMBL4592942

Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3F)n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 20/20 1.00
▸ MAPK11 Q15759 2/20 0.83
▸ BRDT Q58F21 1/20 0.83
▸ BRD4 O60885 1/20 0.78
▸ PRKD3 O94806 1/20 0.75
▸ MAP4K4 O95819 1/20 0.75
▸ HSPB1 P04792 1/20 0.75
▸ PRKCB P05771 1/20 0.75
▸ PRKCA P17252 1/20 0.75
▸ PRKACA P17612 1/20 0.75
▸ CSNK1A1 P48729 1/20 0.75
▸ CSNK1D P48730 1/20 0.75
▸ MINK1 Q8N4C8 1/20 0.75
▸ MAP4K5 Q9Y4K4 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4915397 0.91 MAPK14 (1.00) MAPK14MAPK11BRDTBRD4PRKD3
SCHEMBL6950475 0.91 MAPK14 (1.00) MAPK14MAPK11BRDTBRD4PRKD3
SCHEMBL4913214 0.91 MAPK14 (1.00) MAPK14MAPK11BRDTBRD4PRKD3
SCHEMBL4912070 0.90 MAPK14 (1.00) MAPK14BRDTBRD4
SCHEMBL4915591 0.89 MAPK14 (1.00) MAPK14BRDTBRD4
SCHEMBL4917866 0.88 MAPK14 (1.00) MAPK14BRDTBRD4
SCHEMBL4906584 0.88 MAPK14 (1.00) MAPK14BRDTBRD4
SCHEMBL6948107 0.88 MAPK14 (1.00) MAPK14MAPK11BRDTBRD4PRKD3
SCHEMBL22730415 0.86 MAPK14 (1.00) MAPK14BRDTBRD4
SCHEMBL6943872 0.86 MAPK14 (1.00) MAPK14MAPK11BRDTBRD4PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0900083-B1 NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2003-08-20 — — EP claimed
EP-1539121-A4 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC (US) 2008-08-13 — — EP disclosed
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS PROTTER ANDREW A 2008-05-08 — — US disclosed
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase PROTTER ANDREW A 2008-02-14 — — US disclosed
US-7268139-B2 Methods of promoting osteogenesis SCIOS, INC. (US) 2007-09-11 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed
EP-1676574-A2 Methods for promoting survival of transplanted tissues and cells Johnson & Johnson Vision Care, Inc. (US) 2006-07-05 — — EP disclosed
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase SCIOS INC. 2006-01-26 — — US disclosed
US-20050129729-A1 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. 2005-06-16 — — US disclosed
EP-1539121-A2 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC. (US) 2005-06-15 — — EP disclosed
US-20040171659-A1 Methods for treating diabetes SCIOS, INC. 2004-09-02 — — US disclosed
US-20040162289-A1 Methods of promoting osteogenesis UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY 2004-08-19 — — US disclosed
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase SCIOS, INC. 2004-06-24 — — US disclosed
WO-2004019873-A2 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC. (US) 2004-03-11 — — WO disclosed
EP-0900083-B1 NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2003-08-20 — — EP disclosed
US-6387898-B1 USING IMIDAZOLE COMPOUND SMITHKLINE BEECHAM CORPORATION 2002-05-14 — — US disclosed
US-6096739-A Treatment for CNS injuries SMITHKLINE BEECHAM CORPORATION (US) 2000-08-01 — — US disclosed
US-5977103-A Substituted imidazole compounds SMITHKLINE BEECHAM CORPORATION (US) 1999-11-02 — — US disclosed
US-5864036-A Substituted imidazole compounds SMITHKLINE BEECHAM CORPORATION (US) 1999-01-26 — — US disclosed
US-5756499-A Substituted imidazole compounds SMITHKLINE BEECHAM CORPORATION (US) 1998-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase MAPKAPK5, MAPK1, MAPKAPK2 MAPK14 36/4885MAPK11 39/4885BRDT 3829/4885
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS MAPK1, BMP2, MAPK3 MAPK14 23/4885MAPK11 37/4885BRDT 2959/4885
US-20040162289-A1 Methods of promoting osteogenesis MAPK1, BMP2, MAPK3 MAPK14 23/4885MAPK11 37/4885BRDT 2959/4885
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase OPRK1, OPRL1, MAPK3 MAPK14 36/4885MAPK11 50/4885BRDT 2899/4885
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase OPRK1, OPRL1, MAPK3 MAPK14 36/4885MAPK11 50/4885BRDT 2899/4885
US-20040171659-A1 Methods for treating diabetes SLC5A2, MAPK4, MAPK3 MAPK14 53/4885MAPK11 45/4885BRDT 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.